PeptideStack
5.2kquestions
20kanswers
220users

vomiting

Page 2 of 3 · 57 questions tagged vomiting.

57 questions · sorted by votes · page 2 of 3

22 votes5 answers23k views
What is the reported incidence of vomiting on tirzepatide in SURPASS-3?

Details up front: vomiting · tirzepatide · SURPASS-3. This is presented as though it settles something, and I am not convinced it does. I have two documents that…

vomiting
vomiting

Emesis as a reported adverse event: trial incidence, its relationship to dose escalation rate, dehydration risk, and when it stops being a…

57 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
asked by bea_forsberg 11k · 11 months ago
22 votes0 answers15k views
Is vomiting on orforglipron dose-dependent or dose-rate dependent?

What I have: vomiting · orforglipron. I can predict the outcome but I cannot explain it, which means I will get the next case wrong. I would like to know how…

vomiting
vomiting

Emesis as a reported adverse event: trial incidence, its relationship to dose escalation rate, dehydration risk, and when it stops being a…

57 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
orforglipron
orforglipron

A non-peptide, orally bioavailable small-molecule GLP-1 receptor agonist studied in the ATTAIN programme. It is not a peptide, which changes…

219 questions
asked by samir_bennani 15k · 13 months ago
22 votes2 answers5.5k views
Does holding at 10 mg for six weeks before escalating reduce vomiting?

What I have: 10 mg · six weeks · vomiting. I suspect the usual explanation for this is wrong, or at least incomplete. I am aware this may have a boring answer. I…

titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
vomiting
vomiting

Emesis as a reported adverse event: trial incidence, its relationship to dose escalation rate, dehydration risk, and when it stops being a…

57 questions
dose-escalation
dose-escalation

The decision to move up a step: what evidence supports a four-week interval, what happens when you compress it, and how trial protocols handled…

103 questions
asked by orla_sheridan 18k · 2 months ago
21 votes0 answers26k views
What is the reported incidence of vomiting at the top studied dose?

It has now persisted for three weeks, which is what moved this from tolerable to worth asking about. This is presented as though it settles something, and I am not…

vomiting
vomiting

Emesis as a reported adverse event: trial incidence, its relationship to dose escalation rate, dehydration risk, and when it stops being a…

57 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
gi-side-effects
gi-side-effects

The gastrointestinal cluster as a whole - nausea, vomiting, diarrhoea, constipation, reflux, early satiety - with trial incidence rates, dropout…

162 questions
asked by wren_calloway 23k · 2.1 years ago
19 votes 5 answers33k views
Does holding at 1.7 mg for six weeks before escalating reduce vomiting?

What I have: 1.7 mg · six weeks · vomiting. I suspect the usual explanation for this is wrong, or at least incomplete. I am aware this may have a boring answer. I…

titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
vomiting
vomiting

Emesis as a reported adverse event: trial incidence, its relationship to dose escalation rate, dehydration risk, and when it stops being a…

57 questions
dose-escalation
dose-escalation

The decision to move up a step: what evidence supports a four-week interval, what happens when you compress it, and how trial protocols handled…

103 questions
asked by noor_alhassan 11k · 20 months ago
19 votes 5 answers28k views
What is the reported incidence of vomiting on semaglutide in STEP 3?

The particulars: vomiting · semaglutide · STEP 3. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern is…

vomiting
vomiting

Emesis as a reported adverse event: trial incidence, its relationship to dose escalation rate, dehydration risk, and when it stops being a…

57 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
semaglutide
semaglutide

A GLP-1 receptor agonist with a fatty-acid-acylated backbone and a roughly one-week half-life, marketed for type 2 diabetes and for weight…

470 questions
asked by tabular_nums 71k · 2.0 years ago
19 votes5 answers11k views
Is vomiting on dulaglutide dose-dependent or dose-rate dependent?

The case in front of me: vomiting · dulaglutide. I suspect the usual explanation for this is wrong, or at least incomplete. I am aware this may have a boring answer.…

vomiting
vomiting

Emesis as a reported adverse event: trial incidence, its relationship to dose escalation rate, dehydration risk, and when it stops being a…

57 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
dulaglutide
dulaglutide

A once-weekly GLP-1 receptor agonist built on an Fc fusion rather than fatty-acid acylation. Use this tag for questions about the fusion-protein…

200 questions
asked by lukas_sedlacek 16k · 15 months ago
18 votes 5 answers39k views
What does PIONEER-4 tell me about vomiting at the 7 mg dose?

Setup, so nobody has to ask: PIONEER-4 · vomiting · 7 mg. I would like help reading this properly rather than being told what conclusion to reach. I have the full…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
vomiting
vomiting

Emesis as a reported adverse event: trial incidence, its relationship to dose escalation rate, dehydration risk, and when it stops being a…

57 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
asked by ben_akintola 10k · 20 months ago
18 votes 5 answers23k views
Does holding at 0.5 mg for sixteen weeks before escalating reduce vomiting?

Details up front: 0.5 mg · sixteen weeks · vomiting. I can predict the outcome but I cannot explain it, which means I will get the next case wrong. I would like to…

titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
vomiting
vomiting

Emesis as a reported adverse event: trial incidence, its relationship to dose escalation rate, dehydration risk, and when it stops being a…

57 questions
dose-escalation
dose-escalation

The decision to move up a step: what evidence supports a four-week interval, what happens when you compress it, and how trial protocols handled…

103 questions
asked by rae_oyelowo 17k · 14 months ago
18 votes5 answers7.8k views
What is the reported incidence of vomiting on retatrutide in TRIUMPH-1?

What I have: vomiting · retatrutide · TRIUMPH-1. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to…

vomiting
vomiting

Emesis as a reported adverse event: trial incidence, its relationship to dose escalation rate, dehydration risk, and when it stops being a…

57 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
retatrutide
retatrutide

An investigational GLP-1, GIP and glucagon receptor tri-agonist, studied in the TRIUMPH programme. Not approved anywhere. Use this tag for…

251 questions
asked by cake_intact 17k · 10 months ago
17 votes5 answers36k views
Does vomiting at week seven of liraglutide usually resolve without a dose change?

The specifics, since they change the answer: vomiting · seven · liraglutide. I would like to understand the steps well enough to explain them to someone else. I have…

vomiting
vomiting

Emesis as a reported adverse event: trial incidence, its relationship to dose escalation rate, dehydration risk, and when it stops being a…

57 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
liraglutide
liraglutide

A once-daily GLP-1 receptor agonist and the compound that established the class. Still relevant for its shorter half-life, its paediatric and…

235 questions
asked by low_dead_space 37k · 21 months ago
16 votes 5 answers23k views
Does holding at 5 mg for ten weeks before escalating reduce vomiting?

For reference: 5 mg · ten weeks · vomiting. I understand the observation; what I do not understand is the mechanism behind it. I have read the two review articles…

titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
vomiting
vomiting

Emesis as a reported adverse event: trial incidence, its relationship to dose escalation rate, dehydration risk, and when it stops being a…

57 questions
dose-escalation
dose-escalation

The decision to move up a step: what evidence supports a four-week interval, what happens when you compress it, and how trial protocols handled…

103 questions
asked by esben_lykke 84k · 19 months ago
15 votes 4 answers19k views
What does ESSENCE tell me about vomiting at the 2 mg dose?

Concretely: ESSENCE · vomiting · 2 mg. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the specifics…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
vomiting
vomiting

Emesis as a reported adverse event: trial incidence, its relationship to dose escalation rate, dehydration risk, and when it stops being a…

57 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
asked by kwn_analytical 147k · 18 months ago
14 votes5 answers8.2k views
What did the placebo arm of TRIUMPH-1 report for vomiting?

Concretely: TRIUMPH-1 · vomiting. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a single result, which…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
vomiting
vomiting

Emesis as a reported adverse event: trial incidence, its relationship to dose escalation rate, dehydration risk, and when it stops being a…

57 questions
asked by seamus_brady 15k · 3 months ago
14 votes5 answers5.5k views
When does vomiting stop being a tolerability issue and become a clinical one?

The lane and the lead time matter as much as the material for what I am doing. I am at the decision point and I would rather think it through than improvise. I would…

harm-reduction
harm-reduction

Reducing avoidable risk where a decision has already been made: independent verification before use, sterility practice, dose arithmetic checked…

472 questions
vomiting
vomiting

Emesis as a reported adverse event: trial incidence, its relationship to dose escalation rate, dehydration risk, and when it stops being a…

57 questions
pancreatitis
pancreatitis

Acute pancreatitis as a labelled risk: background incidence, the signal in pooled trial and pharmacovigilance data, lipase interpretation, and the…

30 questions
asked by plunger_stop 13k · 4 months ago
14 votes 5 answers4.2k views
Does holding at 15 mg for ten weeks before escalating reduce vomiting?

The specifics, since they change the answer: 15 mg · ten weeks · vomiting. I understand the observation; what I do not understand is the mechanism behind it. I have…

titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
vomiting
vomiting

Emesis as a reported adverse event: trial incidence, its relationship to dose escalation rate, dehydration risk, and when it stops being a…

57 questions
dose-escalation
dose-escalation

The decision to move up a step: what evidence supports a four-week interval, what happens when you compress it, and how trial protocols handled…

103 questions
asked by kelvin_lam 7.6k · 4 months ago
13 votes5 answers24k views
What does STEP 5 tell me about vomiting at the 2.4 mg dose?

Stated plainly: STEP 5 · vomiting · 2.4 mg. I would like help reading this properly rather than being told what conclusion to reach. I have the full report including…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
vomiting
vomiting

Emesis as a reported adverse event: trial incidence, its relationship to dose escalation rate, dehydration risk, and when it stops being a…

57 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
asked by plate_count_9k 78k · 2.0 years ago
13 votes 4 answers11k views
What is the reported incidence of vomiting on tirzepatide in SURMOUNT-4?

Details up front: vomiting · tirzepatide · SURMOUNT-4. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at…

vomiting
vomiting

Emesis as a reported adverse event: trial incidence, its relationship to dose escalation rate, dehydration risk, and when it stops being a…

57 questions
clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
tirzepatide
tirzepatide

A dual GIP and GLP-1 receptor agonist. Questions here cover the SURPASS and SURMOUNT programmes, the practical differences from a pure GLP-1…

370 questions
asked by fill_volume 22k · 17 months ago
11 votes 5 answers14k views
Does holding at 1.7 mg for three weeks before escalating reduce vomiting?

The specifics, since they change the answer: 1.7 mg · three weeks · vomiting. I would like the mechanism, because I want to be able to reason about the cases nobody…

titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
vomiting
vomiting

Emesis as a reported adverse event: trial incidence, its relationship to dose escalation rate, dehydration risk, and when it stops being a…

57 questions
dose-escalation
dose-escalation

The decision to move up a step: what evidence supports a four-week interval, what happens when you compress it, and how trial protocols handled…

103 questions
asked by m_haraldsen 21k · 18 months ago
10 votes 5 answers8.2k views
Does vomiting at week nine of a GLP-1 receptor agonist usually resolve without a dose change?

For reference: vomiting · nine · a GLP-1 receptor agonist. I want a method I can write down and repeat, not a rule of thumb. I would rather over-engineer this than…

vomiting
vomiting

Emesis as a reported adverse event: trial incidence, its relationship to dose escalation rate, dehydration risk, and when it stops being a…

57 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
asked by ines_delacruz 16k · 15 months ago
9 votes 5 answers26k views
Is vomiting on retatrutide dose-dependent or dose-rate dependent?

Concretely: vomiting · retatrutide. I can predict the outcome but I cannot explain it, which means I will get the next case wrong. I would like to know how confident…

vomiting
vomiting

Emesis as a reported adverse event: trial incidence, its relationship to dose escalation rate, dehydration risk, and when it stops being a…

57 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
retatrutide
retatrutide

An investigational GLP-1, GIP and glucagon receptor tri-agonist, studied in the TRIUMPH programme. Not approved anywhere. Use this tag for…

251 questions
asked by rae_oyelowo 17k · 2.2 years ago
9 votes5 answers13k views
Does holding at 0.5 mg for six weeks before escalating reduce vomiting?

Details up front: 0.5 mg · six weeks · vomiting. I suspect the usual explanation for this is wrong, or at least incomplete. I am aware this may have a boring answer.…

titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
vomiting
vomiting

Emesis as a reported adverse event: trial incidence, its relationship to dose escalation rate, dehydration risk, and when it stops being a…

57 questions
dose-escalation
dose-escalation

The decision to move up a step: what evidence supports a four-week interval, what happens when you compress it, and how trial protocols handled…

103 questions
asked by bea_forsberg 11k · 19 months ago
8 votes5 answers9k views
Does holding at 0.5 mg for ten weeks before escalating reduce vomiting?

The particulars: 0.5 mg · ten weeks · vomiting. I understand the observation; what I do not understand is the mechanism behind it. I have read the two review articles…

titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
vomiting
vomiting

Emesis as a reported adverse event: trial incidence, its relationship to dose escalation rate, dehydration risk, and when it stops being a…

57 questions
dose-escalation
dose-escalation

The decision to move up a step: what evidence supports a four-week interval, what happens when you compress it, and how trial protocols handled…

103 questions
asked by Dr_Idris_Coulibaly 33k · 6 months ago
7 votes0 answers2.8k views
What does SOUL tell me about vomiting at the 7 mg dose?

Stated plainly: SOUL · vomiting · 7 mg. I have read the primary source rather than the summary, which has left me with more questions. I understand the headline. I do…

clinical-trials
clinical-trials

Reading the primary literature properly: estimands, intention-to-treat versus per-protocol, confidence intervals, absolute versus relative…

745 questions
vomiting
vomiting

Emesis as a reported adverse event: trial incidence, its relationship to dose escalation rate, dehydration risk, and when it stops being a…

57 questions
titration
titration

Stepwise dose increases over weeks, why the label schedules exist at all, and what tolerability-driven deviation from a schedule looks like in…

456 questions
asked by bac_or_bust 33k · 16 months ago